Explore

Alamar Biosciences and Nightingale Health Partner with UK Biobank to Identify Early Biomarkers for Neurodegenerative Diseases

Alamar Biosciences and Nightingale Health Partner with UK Biobank to Identify Early Biomarkers for Neurodegenerative Diseases

Alamar Biosciences and Nightingale Health have initiated a collaborative study with the UK Biobank to identify early blood biomarkers for neurodegenerative conditions, including Parkinson’s and Alzheimer’s disease. This project, named UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife, will analyze hundreds of proteins in 80,000 blood samples from UK Biobank participants. The study combines Alamar’s NULISA protein-detection technology, which can detect proteins at very low concentrations using antibodies and DNA-based signals, with Nightingale’s laboratory infrastructure and the UK Biobank’s extensive health data. The goal is to uncover early molecular signatures that could aid in predicting disease risk, improving diagnosis, and guiding future treatment strategies. The study is expected to conclude by the end of 2027, with the resulting data made accessible to approved researchers globally through the UK Biobank Research Analysis Platform.

Policy Center for Maternal Mental Health Convenes Experts on Precision Technology for Diagnosis

Policy Center for Maternal Mental Health Convenes Experts on Precision Technology for Diagnosis

The Policy Center for Maternal Mental Health recently hosted a two-day convening in Marina del Rey, California, focusing on advancing maternal mental health screening and diagnosis through precision technologies. The event, held on October 29–30, 2026, brought together patients with lived experience, clinicians, researchers, and leaders in maternal mental health. Discussions centered on the challenges of current diagnostic methods from both patient and provider perspectives. Experts introduced various emerging precision diagnostic approaches, including biomarkers, neuroimaging, digital technologies, artificial intelligence, and adaptive screening. These presentations initiated conversations about the potential benefits, limitations, concerns, and unanswered questions surrounding these new technologies. The convening was part of a project funded by the Patient-Centered Outcomes Research Institute (PCORI), titled “Convening to Support Engagement in Patient-Centered CER Related to Maternal Mental Health Techn...

Experts at COGC 2026 Emphasize Systemic Investments for Sustainable Precision Oncology

Experts at COGC 2026 Emphasize Systemic Investments for Sustainable Precision Oncology

At the Community Oncology Global Congress (COGC 2026), experts discussed the critical elements for making precision oncology sustainable, particularly outside major academic centers. The panel, moderated by Suman S. Karanth, Additional Director of Medical Oncology at Fortis Memorial Research Institute, included Soham Banerjee, Senior Consultant Genetic Counselor, and Atlal Abusanad, Professor of Medicine and Medical Oncology. The discussion moved beyond the availability of genomic testing to address practical challenges such as drug access when targets are identified, patient understanding of complex results, the utility of molecular tumor boards in smaller settings, and the reliance on Western genomic data. A key consensus was that the sustainability of precision oncology depends not just on the existence of tests but on the robust system built around them. This includes early genetic counseling, local genomic datasets, virtual molecular tumor boards, and better integration of genomic information into ele...

AI-Based Decision Support System Shows Potential to Improve Multiple Myeloma Treatment Consistency

AI-Based Decision Support System Shows Potential to Improve Multiple Myeloma Treatment Consistency

A study published in Frontiers in Medicine investigated the potential of a probabilistic AI-based clinical decision support system, M-BOT, to improve treatment selection in multiple myeloma (MM). The research highlighted significant variability in treatment decisions among hematologists, with inter-expert agreement being extremely low. M-BOT, which integrates probabilistic modeling from clinical trial and real-world data, generated recommendations that were consistently associated with higher predicted response rates compared to physician-selected regimens. While concordance between experts and M-BOT was limited, regimens jointly selected by both demonstrated higher predicted response probabilities. The study suggests M-BOT could enhance consistency and identify more effective treatment options, though further validation in larger, multi-center studies is needed.

AI Model MANTIS Developed to Guide Precision Therapy for Pediatric Brain Tumors

AI Model MANTIS Developed to Guide Precision Therapy for Pediatric Brain Tumors

Researchers have developed an artificial intelligence (AI) model named MANTIS (Methylation profiling and Artificial Neural networks for Time-dependent Individualized Survival predictions) to predict outcomes for pediatric patients with medulloblastoma and ependymoma, two types of brain tumors. Published in Nature Genetics, this AI tool utilizes DNA methylation profiling to provide individualized survival probabilities over a 10-year period. MANTIS was trained using genome-wide DNA methylation array data, including DNA methylation patterns and copy number changes, from 2,786 patients. The model achieved concordance indices up to 0.80 ± 0.07, surpassing the predictive accuracy of current clinical indicators. A key finding is MANTIS's ability to adapt and test radiation therapy treatment intensity, suggesting that approximately 60% of patients with average-risk medulloblastoma might not experience a significant survival disadvantage with less-intensive, lower-dose craniospinal irradiation, potentially leading...

Pharmacogenomics Market Projected to Reach $15.98 Billion by 2030 Driven by AI and Precision Medicine

Pharmacogenomics Market Projected to Reach $15.98 Billion by 2030 Driven by AI and Precision Medicine

The pharmacogenomics market is experiencing rapid growth, with projections indicating it will reach $15.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.2%. This expansion is fueled by increasing investments in precision medicine, the growing adoption of AI-powered genomic analysis, and broader applications in oncology and cardiology. Key trends shaping the industry include personalized medicine adoption, genetic testing for drug selection, integration of pharmacogenomic data into clinical workflows, and the expansion of companion diagnostics. Major companies in this landscape include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, and Thermo Fisher Scientific Inc. Recent strategic moves, such as Genomenon's acquisition of Boston Genetics in June 2023, aim to enhance genomic intelligence capabilities by merging AI platforms with expert genome curation. Innovations like PGxAI's Sirius model, launched in December 2024, are further transforming drug response prediction and man...

Flatiron Health Presents Research on Global Oncology Evidence for Health Technology Assessment at ISPOR Europe 2026

Flatiron Health Presents Research on Global Oncology Evidence for Health Technology Assessment at ISPOR Europe 2026

Flatiron Health Presents Research on Global Oncology Evidence for Health Technology Assessment at ISPOR Europe 2026

Study Reveals Stemness-Associated Transcriptional Profiles in Osteosarcoma, Offering New Prognostic Insights

Study Reveals Stemness-Associated Transcriptional Profiles in Osteosarcoma, Offering New Prognostic Insights

A new research article published in Frontiers in Genetics, specifically in the section on Cancer Genetics and Oncogenomics, details a study on stemness-associated transcriptional profiles in osteosarcoma (OS). The study, titled 'Stemness-associated transcriptional profiles reveal prognostic and microenvironmental heterogeneity in osteosarcoma,' was published on November 6, 2026. Researchers investigated the relationships between stemness-associated gene expression, patient prognosis, and the tumor immune microenvironment in osteosarcoma, an aggressive primary bone malignancy. Using non-negative matrix factorization of stemness-associated gene expression, the study identified two exploratory OS subtypes with distinct prognoses in the TARGET-OS cohort. One subtype (C1) showed poorer survival and enrichment of metabolic and DNA repair programs, while the other (C2) was enriched for extracellular matrix and immune-related processes. The study also developed a nine-gene signature that stratified overall surviva...

GeneDx and Mirum Pharmaceuticals Partner to Offer No-Cost Genetic Testing for Rare Diseases

GeneDx and Mirum Pharmaceuticals Partner to Offer No-Cost Genetic Testing for Rare Diseases

GeneDx and Mirum Pharmaceuticals have announced a collaboration to provide no-cost exome testing for eligible patients suffering from specific rare conditions. These conditions include cholestasis, early-onset cataracts, and peroxisomal biogenesis disorder–Zellweger spectrum disorders (PBD-ZSD). The initiative aims to identify underlying genetic causes to facilitate accurate diagnoses and inform clinical treatment decisions. Through this program, eligible patients will receive GeneDx's ExomeDx™ testing, which offers proband, duo, or trio testing options. Clinicians involved will be provided with a comprehensive clinical report that includes expert interpretation of the results, and GeneDx will also offer post-test genetic counseling to support families and healthcare providers.

Protege Seeks Strategic Partnerships Manager for Wearables to Enhance AI Training Data

Protege Seeks Strategic Partnerships Manager for Wearables to Enhance AI Training Data

Protege Seeks Strategic Partnerships Manager for Wearables to Enhance AI Training Data

Genomic Profiling Uncovers Hidden Cancer Risk Genes, Enhancing Precision Medicine and Prevention

Genomic Profiling Uncovers Hidden Cancer Risk Genes, Enhancing Precision Medicine and Prevention

Researchers at Fondazione Policlinico Universitario A. Gemelli IRCCS have identified genetic alterations associated with cancer predisposition in 10% of patients with solid tumors through next-generation sequencing (NGS) of tumor cells. These alterations, also present in healthy cells, contribute to tumor development and can be inherited by relatives. The study, published in *Genome Medicine*, found that approximately one-third of these hereditary cancer-predisposing syndromes would have been missed by standard diagnostic pathways. The research involved genomic profiling of over 500 genes, revealing constitutional genetic alterations in 1 out of every 10 patients. This comprehensive analysis, part of the FPG500 program, aims to strengthen precision medicine and prevention by guiding therapeutic decisions and informing surveillance strategies for at-risk individuals and their families.

Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics, a California-based biotech company, has released preliminary clinical data for its gene-edited sickle cell disease (SCD) therapy, nula-cel. The data, to be presented at the American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three patients. These patients have also demonstrated restored expression of adult hemoglobin (HbA) and have become transfusion-independent, experiencing no pain crises since receiving their gene-edited hematopoietic stem cells (HSCs). Unlike FDA-approved Casgevy, which increases fetal hemoglobin (HbF), Kamau's nula-cel therapy directly replaces the SCD mutation using homology-directed repair (HDR). The company reports that sickle hemoglobin (HbS) levels fell below 20% of total hemoglobin in two patients who reached the 6-month post-infusion mark. The Phase I/II RESTORE trial is currently enrolling 15 participants.